Citation tools
"Safety and Survival Outcomes of Lutetium-177–Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study." Journal of Nuclear Medicine
(2022):
jnumed.122.264456.
Web. 04 June. 2025.